Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 27 | 2025 | 846 | 7.170 |
Why?
|
| Kidney Failure, Chronic | 4 | 2024 | 952 | 1.440 |
Why?
|
| Depressive Disorder, Major | 4 | 2020 | 453 | 1.420 |
Why?
|
| Fatigue | 4 | 2023 | 201 | 1.090 |
Why?
|
| Sertraline | 4 | 2020 | 45 | 1.080 |
Why?
|
| Antidepressive Agents | 4 | 2025 | 327 | 0.990 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2023 | 1418 | 0.970 |
Why?
|
| Glomerular Filtration Rate | 5 | 2025 | 573 | 0.960 |
Why?
|
| Forearm | 1 | 2024 | 39 | 0.890 |
Why?
|
| Hypertension | 3 | 2022 | 1397 | 0.880 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2024 | 96 | 0.830 |
Why?
|
| Diuretics | 2 | 2022 | 160 | 0.820 |
Why?
|
| Angioedema | 1 | 2023 | 22 | 0.800 |
Why?
|
| Veterans | 3 | 2023 | 1763 | 0.800 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2023 | 68 | 0.790 |
Why?
|
| Renal Dialysis | 4 | 2024 | 947 | 0.770 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 485 | 0.760 |
Why?
|
| Renal Replacement Therapy | 2 | 2023 | 158 | 0.760 |
Why?
|
| Hyperkalemia | 1 | 2023 | 71 | 0.740 |
Why?
|
| Depression | 4 | 2025 | 1350 | 0.710 |
Why?
|
| Acute Kidney Injury | 3 | 2023 | 670 | 0.680 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 277 | 0.660 |
Why?
|
| Antihypertensive Agents | 2 | 2023 | 430 | 0.590 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 118 | 0.560 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 464 | 0.520 |
Why?
|
| Quality of Life | 4 | 2023 | 2159 | 0.520 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2017 | 113 | 0.520 |
Why?
|
| Humans | 39 | 2025 | 132081 | 0.510 |
Why?
|
| Vascular Calcification | 1 | 2017 | 71 | 0.500 |
Why?
|
| Blood Pressure | 2 | 2021 | 1402 | 0.490 |
Why?
|
| Cardiovascular Diseases | 4 | 2025 | 2087 | 0.470 |
Why?
|
| Troponin T | 1 | 2017 | 295 | 0.460 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 342 | 0.440 |
Why?
|
| Atherosclerosis | 2 | 2021 | 1006 | 0.430 |
Why?
|
| Peptide Fragments | 1 | 2017 | 800 | 0.400 |
Why?
|
| Heart Failure | 2 | 2023 | 2398 | 0.390 |
Why?
|
| Urinalysis | 2 | 2024 | 68 | 0.390 |
Why?
|
| Proteinuria | 2 | 2024 | 111 | 0.390 |
Why?
|
| Sex Workers | 1 | 2012 | 5 | 0.390 |
Why?
|
| Practice Guidelines as Topic | 2 | 2025 | 1307 | 0.380 |
Why?
|
| Inflammation | 1 | 2019 | 1522 | 0.370 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2023 | 222 | 0.370 |
Why?
|
| Contact Tracing | 1 | 2012 | 56 | 0.370 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2012 | 95 | 0.350 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 1500 | 0.350 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 742 | 0.340 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 115 | 0.330 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 893 | 0.320 |
Why?
|
| Obesity | 1 | 2021 | 2398 | 0.320 |
Why?
|
| Disease Progression | 3 | 2023 | 2232 | 0.310 |
Why?
|
| Middle Aged | 11 | 2025 | 28980 | 0.300 |
Why?
|
| Creatinine | 4 | 2025 | 413 | 0.290 |
Why?
|
| Female | 15 | 2025 | 70699 | 0.270 |
Why?
|
| Male | 13 | 2025 | 64952 | 0.260 |
Why?
|
| Aged | 9 | 2025 | 21456 | 0.260 |
Why?
|
| Renin-Angiotensin System | 2 | 2023 | 110 | 0.240 |
Why?
|
| Hypoglycemic Agents | 3 | 2021 | 482 | 0.240 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2023 | 137 | 0.230 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 1460 | 0.230 |
Why?
|
| Biomarkers | 3 | 2020 | 3404 | 0.230 |
Why?
|
| Survival Analysis | 2 | 2019 | 1571 | 0.220 |
Why?
|
| Specific Gravity | 1 | 2024 | 4 | 0.220 |
Why?
|
| Erythrocyte Transfusion | 1 | 2025 | 138 | 0.220 |
Why?
|
| Reagent Strips | 1 | 2024 | 11 | 0.220 |
Why?
|
| Adult | 9 | 2025 | 31558 | 0.220 |
Why?
|
| Arm | 1 | 2024 | 77 | 0.220 |
Why?
|
| Prognosis | 3 | 2019 | 5013 | 0.220 |
Why?
|
| Surgical Procedures, Operative | 1 | 2025 | 192 | 0.210 |
Why?
|
| Postoperative Care | 1 | 2025 | 311 | 0.210 |
Why?
|
| Pituitary-Adrenal System | 1 | 2023 | 44 | 0.200 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2023 | 45 | 0.200 |
Why?
|
| Prescriptions | 1 | 2023 | 44 | 0.200 |
Why?
|
| Thiazides | 1 | 2022 | 5 | 0.190 |
Why?
|
| Chlorthalidone | 1 | 2022 | 28 | 0.190 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2022 | 35 | 0.190 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 30 | 0.190 |
Why?
|
| Potassium | 1 | 2023 | 275 | 0.190 |
Why?
|
| Steroids | 1 | 2023 | 174 | 0.190 |
Why?
|
| Retrospective Studies | 4 | 2024 | 17367 | 0.190 |
Why?
|
| Cystatin C | 1 | 2022 | 74 | 0.190 |
Why?
|
| Albuminuria | 2 | 2025 | 113 | 0.180 |
Why?
|
| Anemia | 1 | 2025 | 350 | 0.180 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2021 | 18 | 0.180 |
Why?
|
| Hypotension, Orthostatic | 1 | 2021 | 22 | 0.180 |
Why?
|
| Hematuria | 1 | 2022 | 56 | 0.180 |
Why?
|
| Glucosides | 1 | 2021 | 48 | 0.170 |
Why?
|
| Benzhydryl Compounds | 1 | 2021 | 68 | 0.170 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 7125 | 0.160 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 3086 | 0.160 |
Why?
|
| Risk Factors | 5 | 2025 | 10936 | 0.150 |
Why?
|
| Body Mass Index | 2 | 2022 | 1700 | 0.150 |
Why?
|
| Risk Management | 1 | 2018 | 68 | 0.140 |
Why?
|
| United States | 5 | 2025 | 11652 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2025 | 3727 | 0.130 |
Why?
|
| Aspirin | 1 | 2018 | 220 | 0.130 |
Why?
|
| Hypertension, Pulmonary | 1 | 2021 | 463 | 0.120 |
Why?
|
| Self Report | 1 | 2019 | 553 | 0.120 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 420 | 0.120 |
Why?
|
| Pandemics | 1 | 2023 | 1185 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2022 | 2312 | 0.120 |
Why?
|
| Cause of Death | 1 | 2017 | 507 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2022 | 5169 | 0.110 |
Why?
|
| Coronary Angiography | 1 | 2017 | 487 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2019 | 13015 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1126 | 0.110 |
Why?
|
| Sex Factors | 1 | 2018 | 1352 | 0.110 |
Why?
|
| Disease Management | 1 | 2018 | 565 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2025 | 3129 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 926 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 1249 | 0.100 |
Why?
|
| Comorbidity | 1 | 2018 | 1610 | 0.100 |
Why?
|
| Guatemala | 1 | 2012 | 63 | 0.100 |
Why?
|
| Sexual Partners | 1 | 2012 | 85 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 128 | 0.090 |
Why?
|
| Age Factors | 1 | 2018 | 2921 | 0.090 |
Why?
|
| Patient Preference | 1 | 2012 | 136 | 0.080 |
Why?
|
| Kidney | 1 | 2017 | 1338 | 0.080 |
Why?
|
| Texas | 1 | 2017 | 3632 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2012 | 568 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2019 | 6557 | 0.070 |
Why?
|
| Time Factors | 1 | 2017 | 6443 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3852 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2025 | 242 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2025 | 322 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2025 | 314 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 94 | 0.050 |
Why?
|
| Hospitalization | 2 | 2022 | 1897 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2022 | 277 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2022 | 321 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2025 | 1078 | 0.040 |
Why?
|
| Veterans Health | 1 | 2021 | 179 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 437 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7536 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2022 | 694 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2025 | 1062 | 0.040 |
Why?
|
| Medicare | 1 | 2021 | 447 | 0.030 |
Why?
|
| Infant | 1 | 2012 | 13037 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2022 | 801 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3753 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1653 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 3370 | 0.030 |
Why?
|